Minireviews
Copyright ©The Author(s) 2023.
World J Gastrointest Surg. Mar 27, 2023; 15(3): 323-337
Published online Mar 27, 2023. doi: 10.4240/wjgs.v15.i3.323
Table 1 Landmark trials of perioperative treatment in gastric cancer
Treatment
Study
Arms
n
R0
pCR
PFS
HR (P value)
OS
HR (P value)
Ref.
NACEORTC 40954PF-S7282%NA2-yr: 73%0.84 (0.47)[18]
S alone7267%2-yr: 70%
OEO2PFx2-S40060%NA5-yr: 23%0.84 (0.03)[17]
S alone40254%5-yr: 17%
OE05PFx2-S45159%3%3-yr: 39%0.90 (0.19)[19]
ECXx4-S44666%11%3-yr: 42%
NACRTCROSSRT + pacli-carbo, w-S18092%29%5-yr: 44%0.61 (0.006)5-yr: 47%0.68 (0.003)[21]
S alone18869%5-yr: 27%5-yr: 33%
Perioperative CT (+/-targeted)MAGIC TrialECFx3-S-ECFx325074%8%NR0.66 (< 0.001)5-yr: 36%0.75 (0.009)[22]
S alone25368%NR5-yr: 23%
FNLCC/FCCDPFx2-S-PFx411384%3%5-yr: 34%0.65 (0.003)5-yr: 38%0.69 (0.02)[23]
S alone11173%5-yr: 19%5-yr: 24%
The FLOT-4FLOTx4-S-FLOTx435684.0%15.6%5-yr: 45%0.77 (0.012)[7]
ECX/ECFx3-S-ECX/ECFx336077%5.8%5-yr: 36%
ST03ECXx3-S-ECXx353364%8%3-yr: 50.3%1.08 (0.36)[35]
ECXx3 + BV-S-ECXx3 + BV53061%11%3-yr: 48.1%
PETRARCA (abstract only, ESMO 2020)FLOTx4-S-FLOTx44190%12%26 mo0.57 (0.114)[32]
FLOT + T + Px4-S-FLOT + T + Px4 + 9 (T + P)4093%35%NR
RAMSES[36] (abstract only, ESMO 2020)FLOTx4-S-FLOTx49083%30%
FLOT + RAM x4-S-FLOT + RAM x4 + 16 RAM9097%27%
NAC, adjuvant CT -/+ RTCRITICSECXx3-S-ECXx33935-yr: 39%0.99 (0.9)5-yr: 42%1.01 (0.9)[24]
ECXx3-S-CRT3955-yr: 38%5-yr: 40%
Perioperative CT vs adjuvant CTRESOLVES-XELOXx8345NR3-yr: 51.1%0.86 (0.17) (SOX vs XELOX)[28]
S-SOXx8337NR3-yr: 56.5%
3SOX-S-3SOX365NR3-yr: 59.4%0.77 (0.03) (SOX vs XELOX)
NAC vs CRTPRODIGYDOSX3-S-S1x826695%10%3-yr: 66.3%0.70 (0.023)[29]
S-S-1x826484%3-yr: 60.3%
POETPFLX3-RT (30 Gy)/C-S6271%15.6%3-yr: 47.4%0.67 (0.07)5-yr: 39.5%0.65 (0.055)[66]
PFL2-S6469%2%3-yr: 22.7%5-yr: 24.4%
NEORESCF-RT (40 Gy)-S9187%28%3-yr: 47%(0.77)[64]
CF-S9074%9%3-yr: 49%
Adjuvant CRTINT-0116 trial5FU/LVx1-CRT-5FU/LVx22813-yr: 48%0.66 (0.001)3-yr: 50%0.74 (0.005)[14]
S alone2753-yr: 31%3-yr: 41%
CALGB 80101 Trial5FU/LVx1-CRT-5FU/LVx22803-yr: 46%1.00 (0.99)3-yr: 50%1.03 (0.80)[71]
ECFx1-CRT-ECFx22663-yr: 47%3-yr: 52%
ARTIST trialXPx2-XRT-XP22303-yr: 78%0.74 (0.09)5-yr: 75%1.13 (0.53)[15]
XPx62283-yr: 74%5-yr: 73%
ARTIST trial-2S-1 (x12 mo)1823-yr: 65%0.69 (0.04) (S-1 vs SOX)NRNR[16]
SOX (x6 mo)1813-yr: 74%0.72 (0.07) (S-1 vs SOXRT)NRNR
SOXRT1833-yr: 73%0.97 (0.88) (SOX vs SOXRT)NRNR
Adjuvant CTACTS-GC trialS1 (12 mo)5295-yr: 65%0.655-yr: 72%0.67[14]
S alone5305-yr: 53%5-yr: 61%
CLASSIC trialXELOXx8 (6 mo)5205-yr: 68%0.58 (< 0.0001)5-yr: 78%0.66 (0.53)[11]
S alone5155-yr: 53%5-yr: 69%